BioPharmX Corporation (BPMX) ended last trading session with a change of 7.98 percent. It trades at an average volume of 1.03M shares versus 1.95M shares recorded at the end of last trading session. The share price of $0.48 is at a distance of 152.71 percent from its 52-week low and down -68.95 percent versus its peak. The company has a market cap of $32.93M and currently has 69.32M shares outstanding. The share price is currently 5.05 percent versus its SMA20, 7.78 percent versus its SMA50, and -9.54 percent versus its SMA200. The stock has a weekly performance of 1.09 percent and is 27.03 percent year-to-date as of the recent close.
March 13, 2017 — BioPharmX Corporation (BPMX), a specialty pharmaceutical company developing products for the dermatology market, will share scientific data at the 55th Annual Meeting of the Society of Toxicology (SOT), which will suggest the company’s novel topical gel BPX-01 delivers acne-fighting medication to the target area safely without systemic side effects.
A poster on the research, titled “BPX-01 Toxicological Evaluation of 1% Topical Minocycline Gel,” will be presented at the Baltimore meeting from 1:15 p.m. to 4:30 p.m. on March 14 (poster number P511). The SOT meeting is one of the world’s largest gatherings of toxicologists.
Regulus Therapeutics Inc. (RGLS) recently recorded 8 percent change and currently at $1.35 is 43.62 percent away from its 52-week low and down -84.83 percent versus its peak. It has a past 5-day performance of 19.47 percent and trades at an average volume of 891.86K shares. The stock has a 1-month performance of 8 percent and is -40 percent year-to-date as of the recent close. There were about 52.96M shares outstanding which made its market cap $71.5M. The share price is currently 18.06 percent versus its SMA20, -19.94 percent versus its SMA50, and -55.4 percent versus its SMA200.
On March 2, 2017 Regulus Therapeutics Inc. (RGLS) reported financial results for the fourth quarter and full year ended December 31, 2016 and provided a summary of corporate highlights and pipeline update.
Fourth Quarter 2016 Highlights
- Initiated a Phase I MAD study for RG-012: Data from this study in healthy volunteers will provide additional PK and safety data and will be available in the second quarter 2017. The Phase II HERA study is expected to resume in the second half of 2017 following completion of the MAD study.
- Announced two new clinical candidates at the Company’s first R&D Day: RGLS5040 (anti-miR-17) for the treatment of cholestatic diseases; and RGLS4326 (anti-miR-27) for the treatment of autosomal dominant polycystic kidney disease (ADPKD). IND-enabling activities are currently underway. Regulus expects to file the INDs in the second half of 2017.
- Attracted Key Talent: Dr. Timothy Wright joined Regulus in October as its Chief R&D Officer.